Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer

Hellenic Society of Medical Oncology300 enrolled

Overview

• To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece

* To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece * To evaluate the outcome of patients per treatment line (objective response, progression free survival, time to disease progression per line of therapy), overall survival * To record adverse events per line of therapy * To recording of the causes of treatment discontinuation per line of therapy

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Metastatic Breast Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women with histological confirmed ER/PR positive, HER2-negative MBC * Age \>18 years old * Patients initiating first or second line therapy for ER/PR positive, HER2-negative MBC * Adequate hematologic, renal and hepatic function * Signed informed consent (ICF) Exclusion Criteria: * Active malignancy other than MBC * Active infection

Locations (1)

Hellenic Society of Medical Oncology

Athens, Greece

RECRUITING

Outcomes

Primary Outcomes

Evaluation of the outcome per treatment line

To evaluate the outcome of patients per treatment line (objective response, progression free survival, time to disease progression per line of therapy), overall survival

Time frame: 5 years

Central Contacts

Sofia Agelaki, prof

CONTACT

+302106457971 agelakisofia@gmail.com

Kalliopi Sarikaki

CONTACT

+302106457971 psarikaki@hesmo.gr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.